{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:18:07Z","timestamp":1788365887016,"version":"build-2803163510"},"reference-count":16,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"abstract":"\n Importance<\/jats:title>\n Antidepressant efficacy of intravenous (IV) ketamine has been demonstrated in major depressive disorder; however, the efficacy and safety of ketamine for bipolar depression remain largely unknown, with limited data available in this specific population.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy, safety, and tolerability of adjunctive IV ketamine compared with midazolam for treatment-resistant bipolar I or II depression (TRBD).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n The Ket-BD study (Ketamine for Treatment-Resistant Bipolar Disorder) was an investigator-led, double-blind, midazolam-controlled randomized clinical trial conducted at 3 sites in Ontario, Canada, from July 2022 to November 2025. Participants included adult outpatients (aged 21-65 years) with a primary bipolar I or II disorder\n DSM-5<\/jats:italic>\n diagnosis with a current moderate to severe major depressive episode (Montgomery-\u00c5sberg Depression Rating Scale [MADRS] score \u226521), having had at least 2 failed trials of evidence-based pharmacotherapies. Data were analyzed from November 2025 through February 2026.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized 1:1 to receive 4 flexibly dosed 40-minute infusions over 2 weeks of either ketamine (0.5-0.75 mg\/kg) or midazolam (0.02-0.03 mg\/kg) adjunctive to a stable dose of at least 1 mood stabilizer or antipsychotic.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was change in depression symptom severity measured by the observer-rated MADRS score from baseline to end of treatment (day 14). Safety and tolerability were assessed with close evaluation for potential treatment-emergent mania, hypomania, mixed features, or psychosis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 68 randomized participants (mean [SD] age, 44.4 [11.8] years; 38 female [55.8%]), 63 were included in the final efficacy analysis as 5 participants withdrew (1 ketamine, 4 midazolam) before the primary end point. In the primary efficacy analysis, controlling for sex, bipolar type, and baseline MADRS, the mean MADRS score at day 14 was significantly lower in the ketamine group compared to the midazolam group (between-group difference\u2009=\u2009\u22127.3 points; 95% CI, \u221212.0 to \u22122.5;\n P<\/jats:italic>\n \u2009=\u2009.003; Cohen\n d<\/jats:italic>\n \u2009=\u20090.7). No cases of mania, hypomania, psychosis, or suicide attempts were observed in either group. One case of mixed features (subthreshold hypomanic symptoms) was observed in each group. After the first infusion, 31 of 66 participants (47%) correctly guessed treatment allocation.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In TRBD, adjunctive IV ketamine was well tolerated and associated with significant antidepressant effects compared to midazolam.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05004896<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.2658","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:30:25Z","timestamp":1788363025000},"source":"Crossref","is-referenced-by-count":0,"title":["Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression"],"prefix":"10.1001","author":[{"given":"Diana K.","family":"Orsini","sequence":"first","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Di Luch","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle F. M.","family":"Lovell","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Vasudeva","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Neuropsychology Track, Department of Psychology, University of Windsor, Windsor, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica E.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair J.","family":"Flint","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Centre for Mental Health, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian-Daniel","family":"Llach","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Karkouti","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Pain Management, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Burhan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Ontario Shores Centre for Mental Health Sciences, Whitby, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Kaczmarek","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Chisamore","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Anesthesia and Pain Management, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neilesh","family":"Soneji","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Pain Management, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Pain Management, University Health Network, Toronto, Ontario, Canada"},{"name":"Ontario Shores Centre for Mental Health Sciences, Whitby, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Grewal","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Pain Management, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Laframboise","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Pain Management, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Centre for Mental Health, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ybr260005r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis.","volume":"62","author":"Nikolin","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"5","key":"ybr260005r2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation.","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"issue":"4","key":"ybr260005r3","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15376","article-title":"Efficacy and safety of ketamine\/esketamine in bipolar depression in a clinical setting.","volume":"85","author":"Santucci","year":"2024","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"ybr260005r4","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamapsychiatry.2025.3019","article-title":"Serial ketamine infusions as adjunctive therapy to inpatient care for depression: the KARMA-Dep 2 randomized clinical trial.","volume":"82","author":"Jelovac","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ybr260005r5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067194","article-title":"Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial.","volume":"376","author":"Abbar","year":"2022","journal-title":"BMJ"},{"key":"ybr260005r6","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231202723","article-title":"Ketamine for bipolar depression: an updated systematic review.","volume":"13","author":"Fancy","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"issue":"3","key":"ybr260005r7","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.20l02811","article-title":"Ketamine-induced manic episode.","volume":"23","author":"Bhatt","year":"2021","journal-title":"Prim Care Companion CNS Disord"},{"issue":"11","key":"ybr260005r8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"3","key":"ybr260005r9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bdi.12487","article-title":"Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial.","volume":"19","author":"Grunebaum","year":"2017","journal-title":"Bipolar Disord"},{"issue":"8","key":"ybr260005r10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch Gen Psychiatry"},{"issue":"22","key":"ybr260005r11","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 statement: updated guideline for reporting randomized trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"ybr260005r12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"issue":"11","key":"ybr260005r13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","article-title":"Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.","volume":"9","author":"Smith-Apeldoorn","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"ybr260005r14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamapsychiatry.2026.0255","article-title":"Blinding integrity in psychedelic randomized clinical trials: a systematic review.","volume":"83","author":"Orsini","year":"2026","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"ybr260005r15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/ijnp\/pyz064","article-title":"The CINP guidelines on the definition and evidence-based interventions for treatment-resistant bipolar disorder.","volume":"23","author":"Fountoulakis","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10506","key":"ybr260005r16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(25)01140-7","article-title":"Bipolar disorder.","volume":"406","author":"Singh","year":"2025","journal-title":"Lancet"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2853662\/jamapsychiatry_orsini_2026_br_260005_1787858957.64106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:30:26Z","timestamp":1788363026000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2853662"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.2658","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}